Login to Your Account

ILEX Drops Bladder Cancer Drug After Phase III Failure

By Karen Pihl-Carey

Tuesday, January 20, 2004
ILEX Oncology Inc.'s drug eflornithine (DFMO) failed to reach statistical significance in a Phase III trial with superficial bladder cancer patients, resulting in the company's decision to discontinue development. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription